Delek US Holdings Inc
10 nominees · 4 ballot items.
Elect ten directors; advisory approval of the Company’s executive compensation (say-on-pay); approval of the 2026 Long-Term Incentive Plan to replace the 2016 Plan; and ratification of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026.
Follow how the vote landed and what changed on Delek US Holdings Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot4
- 1
Election of Ten Directors
ManagementBoard: FORElect ten directors of the Company to serve until the 2027 Annual Meeting of Stockholders or until their respective successors are appointed, elected and qualified.
- 2
Advisory Resolution on Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
More detail
This advisory (non-binding) 'say-on-pay' proposal asks stockholders to approve the Company’s executive compensation program as disclosed in the proxy, encompassing the Compensation Discussion and Analysis, compensation tables, and related narrative. Management seeks shareholder endorsement to confirm alignment between pay and performance, and to validate the overall structure that emphasizes a majority of pay at risk and long-term, equity-based incentives (RSUs and PSUs) tied to TSR and Delek Logistics metrics. The Company’s compensation framework also included an Annual Incentive Plan (AIP) with metrics (Adjusted EBITDA, operating and safety measures) and an equity-based Enterprise Optimization Plan (EOP) tied to cost savings, both of which materially affected 2025 payouts. The Board cites historical shareholder support and engagement—noting prior say-on-pay approval levels—as evidence of alignment and uses the advisory vote as a governance feedback mechanism rather than a binding directive. Management’s counterpoint in the proxy is that the program balances recruitment/retention needs with pay-for-performance, referencing consultant benchmarking and objective metrics and limiting fixed compensation. If approved, the advisory vote would signal to the Board that investors support the incentive design; a significant adverse vote would prompt the Board and Compensation Committee to consider and respond to stockholder concerns. The Board recommends a 'FOR' vote, emphasizing that it values investor feedback but retains discretion over compensation design and implementation.
- 3
Approval of the 2026 Long-Term Incentive Plan
ManagementBoard: FORApprove the 2026 Long-Term Incentive Plan (the “2026 Plan”) to replace the 2016 Plan (which expires in 2026) to permit future grants of equity and cash incentive awards to employees, consultants and nonemployee directors.
More detail
This proposal asks stockholders to approve a new long-term incentive plan to succeed the 2016 Plan, which the Company states expires by its terms in 2026. Management is seeking authority to continue using equity- and cash-based awards to recruit, retain and motivate employees, consultants and non-employee directors; without approval, the Company would be unable to grant new awards under the expired plan. The 2026 Plan as summarized in the proxy incorporates several governance-oriented features — including limits on annual awards to individuals, minimum vesting requirements for options/SARs, prohibited repricing without stockholder approval, clawback applicability, and a double-trigger change-in-control approach — which the Board highlights as best-practice protections against dilution and misaligned incentives. The Plan also uses a share-counting convention (e.g., certain full-value awards count as 1.74 shares) and contains customary adjustment provisions to preserve award economics in corporate transactions, which materially affects the reserve’s effective capacity. Approval would permit continued issuance of RSUs, PSUs, options and other award types that tie executive and director pay to company performance (including relative TSR and distributable cash flow metrics used elsewhere in compensation). The Board recommends a 'FOR' vote citing the operational need for an equity plan to execute compensation programs, the inclusion of investor-friendly plan features, and the importance of ongoing alignment between the interests of management and stockholders. From a governance perspective, investors should evaluate the requested share reserve, individual award limits, performance metric design, reuse rules for returned shares, and anti-dilution adjustments when deciding whether the plan’s dilution and protections are appropriate relative to peer practice. If approved, no further awards will be granted under the 2016 Plan and the Company will transition grant activity to the 2026 Plan.
- 4
Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Nominees on the ballot10
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.9% | 3,634,497 | $164M |
| 2 | STATE STREET CORP | 5.0% | 3,047,971 | $137M |
| 3 | Rubric Capital Management LP | 4.4% | 2,687,449 | $121M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,616,850 | $118M |
| 5 | River Road Asset Management, LLC | 4.0% | 2,480,378 | $112M |
| 6 | BlackRock, Inc. | 3.8% | 2,330,590 | $105M |
| 7 | GOLDMAN SACHS GROUP INC | 3.5% | 2,124,393 | $96M |
| 8 | TWO SIGMA INVESTMENTS, LP | 3.1% | 1,899,965 | $86M |
| 9 | BlackRock, Inc. | 3.1% | 1,876,694 | $85M |
| 10 | Allianz Asset Management GmbH | 3.0% | 1,818,612 | $82M |
Other Energy sector meetings6
Upcoming shareholder meetings at Delek US Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Delek US Holdings Inc 2026 annual meeting?
- Delek US Holdings Inc (DK) holds its 2026 annual shareholder meeting on Monday, April 20, 2026.
- What is the record date for the Delek US Holdings Inc 2026 meeting?
- The record date for the Delek US Holdings Inc 2026 meeting is Friday, February 27, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Delek US Holdings Inc's 2026 meeting?
- The board is presenting 10 director nominees at the Delek US Holdings Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Delek US Holdings Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Delek US Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.